

REFLECT SCIENTIFIC INC
Form 10-K
March 31, 2010

U. S. Securities and Exchange Commission

Washington, D. C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

ACT OF 1934

For the fiscal year ended December 31, 2009

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

ACT OF 1934

For the transition period from _____ to _____

Commission File No. - 000-313770

REFLECT SCIENTIFIC, INC.

(Name of Small Business Issuer in its Charter)

Utah

87-0642556

(State or Other Jurisdiction of

(I.R.S. Employer Identification No.)

incorporation or organization)

1270 South 1380 West

Orem, Utah 84058

(Address of Principal Executive Offices)

Issuer's Telephone Number: (801) 226-4100

Securities registered under Section 12(b) of the Act: None

Name of Each Exchange on Which Registered: None

Securities registered under Section 12(g) of the Act:

\$0.01 par value common stock

Title of Class

Check whether the Issuer is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. []

Check whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. (1) Yes [X] No (2) Yes [X] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). The registrant has not been phased into the Interactive Data reporting system. Yes [X] No []

Edgar Filing: REFLECT SCIENTIFIC INC - Form 10-K

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of Issuer's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. []

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large Accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the Issuer is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

State Issuer's revenues for its most recent fiscal year: December 31, 2009 - \$5,658,125.

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked prices of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter: \$4,336,176

There are approximately 18,067,400 shares of common voting stock of the Issuer held by non-affiliates, and based upon the average bid and asked prices of our common stock on March 30, 2010 of \$0.11, as reported by the OTC Bulletin Board of the National Association of Securities Dealers, Inc., the aggregate market value of our common stock held by non-affiliates was approximately \$1,987,414.

Issuers Involved in Bankruptcy Proceedings During the Past Five Years

None; not applicable.

Check whether the Issuer has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. Yes No

Not applicable.

Applicable Only to Corporate Issuers

State the number of shares outstanding of each of the Issuer's classes of common equity, as of the latest practicable date:

March 30, 2010: Common 35,221,650

Documents Incorporated by Reference

A description of Documents Incorporated by Reference is contained in Part III, Item 13, of this Annual Report.

Transitional Small Business Issuer Format Yes [] No [X]

TABLE OF CONTENTS

PART I	..	4
Item 1. Description of Business		.4
Item 1a. Risk Factors		10
Item 2. Description of Property	..	10
Item 3. Legal Proceedings		10
Item 4. Submission of Matters to a Vote of Security Holders		. 11
PART II		11
Item 5. Market for Common Equity and Related Stockholder Matters and Small Business Issuer Purchases of Equity Securities		. 11
Item 6. Select Financial Data		12
Item 7. Management's Discussion and Analysis or Plan of Operation		12
Item 7a. Quantitative and Qualitative Disclosure About Market Risk		. 15
Item 8. Financial Statements		15
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure		.15
Item 9(A)T. Controls and Procedures		..15
Item 9(B). Other Information		16
PART III		16
Item 10. Directors, Executive Officers, Promoters and Control Persons; Compliance with Section 16(a) of the Exchange Act		. 16
Item 11. Executive Compensation		18

Edgar Filing: REFLECT SCIENTIFIC INC - Form 10-K

Item 12. Security Ownership of Certain Beneficial Owners and Management	20
Item 13. Certain Relationships and Related Transactions	. 21
Item 14. Principal Accounting Fees and Services	. 21
Item 15. Exhibits	23
SIGNATURES	24

Forward-Looking Statements

When used in this Annual Report on Form 10-K, the words or phrases would be, will allow, intends to, will likely result, are expected to, will continue, is anticipated, estimate, project or similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements specifically include, but are not limited to, our expectations regarding strategic business initiatives, our intentions to defend our intellectual property rights, continue our research and development, seek regulatory approvals and plans regarding sales and marketing.

We caution readers not to place undue reliance on the forward-looking statements, which speak only as of the date of this Annual Report, are based on certain assumptions and expectations which may or may not be valid or actually occur and which involve various risks and uncertainties, including but not limited to competitive products and pricing, difficulties in product development, commercialization and technology, changes in the regulation of life science products, or other necessary approvals to sell future products and other risk described elsewhere herein. If and when sales of our new product lines commence, sales may not reach the levels anticipated. As a result, our actual results for future periods could differ materially from those anticipated or projected. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

PART I

Item 1. Description of Business

Business Development

History

Reflect Scientific, Inc., a Utah corporation (the Company, we, our, us and words of similar import), was organized under the laws of the State of Utah on November 3, 1999, under the name Cole, Inc. On December 31, 2003, we acquired Reflect Scientific, Inc., a California corporation. We changed our name to Reflect Scientific, Inc. and succeeded to the business operations of our wholly-owned subsidiary, that involved the manufacture and distribution of unique laboratory consumables and disposables such as filtration and purification products, customized sample handling vials, electronic wiring assemblies, high temperature silicone, graphite and vespel/graphite sealing components for use by original equipment manufacturers (OEM) in the chemical analysis industries, primarily in the field of gas/liquid chromatography. See our 8-K Current Report dated December 31, 2003, which was filed with the Securities and Exchange Commission on January 15, 2004, and is incorporated herein by reference. See Part III, Item 13.

On November 29, 2005, we announced the execution of a Letter of Intent to acquire Cryomastor Corporation, a California corporation (Cryomastor [sometimes called Cryometrix, its amended name]).

Effective as of April 4, 2006, we entered into a Purchase Agreement (the JMST Agreement) with JM SciTech, LLC, a limited liability company organized under the laws of the State of Colorado, and doing business as JMST Systems (JMST); David Carver, an individual (Carver); and Julie Martin, an individual (Martin) (JMST, Carver and Martin are sometimes hereinafter referred to collectively as Sellers). Pursuant to the JMST Agreement, we purchased and JMST sold all right, title and interest in and to the JMST Technology (the JMST Technology), as described in the JMST Agreement; and Carver conveyed and assigned any rights he had in and to certain patents (the Carver Patents) and related intellectual assets as described in the JMST Agreement (collectively, including the Carver Patents, referred to herein as the Carver Technology). JMST had created a line of chemical detection instruments that are used in the pharmaceutical, biotechnology and homeland security markets. The patented technology allows researchers to accurately analyze chemical formulations for their composition and identity. See our 8-K Current Report dated April 4, 2006, which was filed with the Securities and Exchange Commission on April 7, and is incorporated herein by reference. See Part III, Item 13.

On June 27, 2006, we completed the acquisition of Cryomastor pursuant to an Agreement and Plan of Merger (the Cryomastor Merger Agreement), which became our wholly-owned subsidiary; changed its name to Cryometrix, Inc. ; and succeeded to its business operations, which involved the manufacture and sale of ultra low temperature freezer systems powered by liquid nitrogen for use in bio-repositories associated with the biotech and pharmaceutical industries, as well as

government facilities, universities and many other diverse applications that require a large number of reliable and energy efficient freezers. See our 8-K Current Report dated June 27, 2006, which was filed with the Securities and Exchange Commission on June 30, 2006, and is incorporated herein by reference. See Part III, Item 13.

On November 15, 2006, we entered into an Agreement and Plan of Merger (the Image Labs Merger Agreement) between Image Acquisition Corp., a Georgia corporation and our wholly-owned subsidiary (Merger Subsidiary); Smithgall & Associates, Inc., dba Image Labs International, a Georgia corporation (Image Labs); and Brian Smithgall (Smithgall), the sole shareholder of Image Labs (the Image Labs Shareholder). Established in 1993 and located in Bozeman, Montana, Image Labs is a manufacturer and developer of factory automation equipment. The primary product lines focus in the areas of automated inspection, measurement and material handling. See our 8-K Current Report dated November 15, 2006, which was filed with the Securities and Exchange Commission on November 21, 2006, and is incorporated herein by reference. See Part III, Item 13. In February 2010, management made the decision to divest this business. See Footnote 18 Subsequent Events in the financial statements.

On November 17, 2006, we entered into an Agreement and Plan of Merger (the The All Temp Merger Agreement) between our wholly-owned subsidiary, Cryometrix, Inc. (Merger Subsidiary); All Temp Engineering Inc., a California corporation (All Temp); J F Dain & E L Dain CO T Tee Dain Family Revocable Trust U/A Dated 12/17/2001 (the Dain Trust) and Nicholas J. Henneman (Henneman), the sole All Temp Shareholders (collectively, the All Temp Shareholders); and John F. Dain, individually (Dain). All Temp was located in San Jose, California and has been providing engineered solutions and services to the cryogenics industry for over 24 years. All Temp served numerous companies in business sectors such as biotech, pharmaceutical, medical devices, research, universities, semiconductor, aerospace, military, and industrial food processing. See our 8-K Current Report dated November 17, 2006, which was filed with the Securities and Exchange Commission on November 22, 2006, and is incorporated herein by reference. See Part III, Item 13.

On June 29, 2007, we completed the sale of \$2,500,000 of debentures. See our 8-K Current Report dated July 2, 2008, and is incorporated herein by reference. See Part III, Item 13.

Business

Overview

Reflect Scientific is engaged in the manufacture and distribution of innovative products targeted at the life science market. Our customers include hospitals and diagnostic laboratories, pharmaceutical and biotech companies, universities, government and private sector research facilities, and chemical and industrial companies.

Our goal is to provide our customers with the best solution for their needs. This philosophy extends into our business strategies and acquisition plans. Through a series of strategic acquisitions in 2006 and 2007, we now offer a greatly expanded line of products that take advantage of market needs. Our growing product portfolio includes ultra low temperature freezers and chemical detectors, in addition to supplying OEM products to the life science industry.

Our Visacon brand chemical detectors provide our OEM customers a cost effective detection product that allows them to extend their markets. Detectors use patented optical detection technologies that can be tailored for pharmaceutical, biotechnology or other life science applications.

Our Cryometrix brand ultra low temperature freezers innovative design enables our customers to save substantially on energy costs related to cryogenic storage. Ultra low temperature freezers are used world-wide for the storage of vaccines, DNA, RNA, proteins and many other biological and chemical samples. There is a growing need for energy efficient, reliable ultra low temperature storage units. We will continue to expand into this growing market with the Cryometrix freezer. The application of this technology for use in refrigerated trailers (commonly called reefers) used to transport goods which need to be maintained in a cold environment significantly broadens the market for this technology. The utilization of this technology to reefers eliminates the current method of cooling, which uses engines run on hydrocarbon fuels. The Cryometrix technology is pollutant free and is more cost effective and efficient than technologies currently being used.

Products

Reflect Scientific designs, develops and sells scientific equipment for the Life Science and Manufacturing industries. Since our wholly owned subsidiary, Reflect Scientific s, organization in 1991, our focus is and has been on providing value added products, analytic testing equipment and stand alone products for the life science and industrial market place. Reflect Scientific s products range from non-mechanical Cyrometrix freezers, products and parts for life science industry to tools and analytical services for industrial manufacturing.

All of Reflect Scientific's products and services are developed with one key factor in mind: Do they provide a superior cost/benefit to the customer than other products in the same market space. With years of experience in the life science and industrial manufacturing markets, Reflect Scientific has been able to develop not only unique patentable products, but products that we believe offer immediate advantages and cost savings over any other competing and existing products on the market.

We have developed a business model with a focus on intellectual expertise in design and development of products and solutions for life science and industrial manufacturing industries. We outsource the majority of our manufacturing, allowing us to maintain the flexibility to develop products across multiple lines and industries. Our strength is in providing products which we believe offer immediate, verifiable, cost saving solutions.

We have found many companies that can manufacture products to our specification, allowing us to focus on our core competencies of development and design and maintain a flexible corporate structure capable of taking advantage of new opportunities without the large capital investment required to acquire tooling and manufacturing equipment. This focus on the intellectual expertise as opposed to manufacturing of products also allows us to develop products along multiple industry lines and to tailor our products to specific needs in a variety of industrial settings. Our products are sold in the biotechnology, pharmaceutical and medical industries, as well as the manufacturing industries such as automotive.

Cryometrix Freezers

Our Cryometrix ultra low temperature freezers are, we believe, a technological breakthrough that provides energy savings and other critically important benefits to cryo-storage customers in the Life Science related industries. Ultra low temperature freezers are used in multiple industries for the storage of everything from blood to cancer vaccines. These freezers are used by companies and organizations such as the Red Cross, hospitals and biotechnology research facilities.

The only ultra low temperature freezers currently available are produced by a limited number of companies and rely on a mechanical process for cooling. Because of inadequacies in the mechanical process, we believe there is wastage of inventory each year because of the problems of proper cooling found in the mechanical freezers.

Our freezers are a complete divergence from the current technology used in ultra low temperature freezers. Through the advantages of our technology, we believe our freezers solve the current inadequacies and provide immediate cost savings for our clients. Current cryogenic storage equipment falls short of customer expectations in a variety of key performance criteria.

§

High energy usage a growing problem with rising energy costs

§

Inflexible temperature range existing units cannot be easily modified for colder requirements (colder temperatures are an industry trend)

§

Sample inventory is at risk in the event of a power failure

§

Poor temperature uniformity samples in different areas of the freezer can experience wide variations in temperatures which is undesirable from a regulatory standpoint.

Our Cryometrix ultra low temperature freezer uses a new patented design which is powered by liquid nitrogen. Through the use of a liquid nitrogen powered freezer system we are able to address the market need for:

§

Low energy requirements

§

Flexible temperature control wide range of usable temperatures

§

Power failures have little effect - uses passive liquid nitrogen technology rather than electrically powered compressors.

§

Uniform temperatures throughout freezer more usable storage volume

§

Much larger storage volume per area of floor space occupied reduced facilities cost

§

Reliable and essentially maintenance free; further lowering cost of ownership

We believe existing freezers are outdated and our freezers will be the desired technology to which the industry will move, providing us the opportunity to gain a significant market share in this large market.

The adaptation of the freezer technology to refrigeration systems used on trailers (reefers) for transporting perishable items opens a significant new market. Trailers can easily be retrofit with the Cryogenix unit, which provides pollutant free and more efficient operations at a cost savings compared to the diesel powered units currently used. The reefer market is a \$1 billion market. The non-polluting Cryogenix unit provides significant benefits over any other unit

currently marketed.

Detectors

Our chemical detector products serve the analytical instrumentation sector of the Life Sciences market. These optically based chemical detection instruments provide a cost-effective, high-performance alternative for original equipment manufacturers (OEM). One major use for these detectors is the analysis of whole blood for metabolic diseases.

Companies that manufacture beneficial chemicals or biotechnology products are often required to develop a methodology to detect their presence in the environment or in living tissue. Recent market trends have been toward the creation of a dedicated system that is specific for a particular chemical. As the market expands for dedicated instrumentation, certain critical issues arise.

§

Lack of high quality, high performance OEM instrumentation - large instrument manufacturers sell the service/instrument combination only under their own brand name

§

High price points - instrument company structure does not allow value pricing

Our products provide the building blocks to create such a system. Patented technology provides an array of benefits to the OEM customer.

§

High performance instrumentation - meets or exceeds industry standards for chemical detection

§

Technological breakthroughs provide cost-effective detection instrument solutions

§

Versatile configurations allow tailoring to specific customer need without the necessity for expensive custom engineering

§

Certified by various regulatory agencies for sale worldwide

With the expanding focus on the need for detectors we designed a base system that can be tooled for multiple uses offering flexibility to our customers. We intend to further penetrate the dedicated OEM instrument market through new product development and continued cost reductions in manufacturing to meet price points.

Reflect Scientific is also poised to provide consumables to the same group of customers that purchase detectors. This one stop shopping is very attractive to customers and is unique in the OEM supply industry, further making Reflect Scientific the choice for OEMs.

Inspection and Testing Equipment

Our inspection and testing equipment product lines were sold effective March 2, 2010. See Footnote 18 Subsequent Events to the financial statements.

Competition

The environment for our products and services is intensely competitive. Although the complexity of the products we produce limits the number of companies we compete with, the companies with competing technology are generally larger and often subsidiaries or divisions of very large multinational companies. Our competitors size and association with large multinational companies gives them advantages over us in the ability to access potential customers. Many potential customers already purchase products either directly from our competitors or from another subsidiary of these large multinational companies, creating natural inroads to sales that we do not possess.

Given our relative size verses our competitors, we often have to seek niche markets for our products or focus on selling components to be used in our competitors larger detection units. We believe, however, that our technology and experience in the ultra low freezers and detectors allows us to be competitive in those markets. However, since our products are new to the marketplace, the products long term commercial acceptance is still unknown. Most of our products compete against multiple competitors, with our refrigeration products competing primarily against Thermo Fisher Scientific and Sanyo Corporation.

Growth Plan

We continue to evaluate acquisitions of businesses and technologies to enhance our revenues in the Life Science and green technology markets. In addition to organic growth with our existing product lines we will continue to research and investigate acquisitions which match our core commitment in order to grow our Company and enhance shareholder value.

We intend to seek to expand the applications for our products and equipment into additional markets as we develop brand recognition. We hope to be able to leverage off of our existing products and name recognition as we continue forward using

our existing offerings and product strength to position us as a key supplier of automation equipment, inspection equipment and cryogenic storage solutions. This strategic plan will also allow for further diversification of our customer base.

Manufacturing, Supplies, and Quality Control

Many of our products are manufactured by third party manufactures, including our ultra low temperature freezers. We believe by outsourcing our manufacturing we are able to reduce the overall cost of our products. We do manufacture some products which are less labor and parts intensive in our facility in Orem, Utah.

Regulation and Environmental Compliance

Presently, none of our products are in highly regulated industries.

Sources and Availability of Raw Materials and Names of Principal Suppliers

Sources and availability of key materials and intermediates continue to remain stable. Where supply is considered a critical success factor for our business, we have certified vendors in place.

Dependence on One or a Few Major Customers

We are not dependent on any large customer.

Need for any Governmental Approval of Principal Products or Services

No products presently being manufactured or sold by us are subject to prior governmental approvals.

Effect of Existing or Probable Governmental Regulations on the Business

The integrated disclosure system for small business issuers adopted by the Securities and Exchange Commission in Release No. 34-30968 and effective as of August 13, 1992, substantially modified the information and financial requirements of a Small Business Issuer, defined to be an issuer that has revenues of less than \$25 million; is a U.S. or Canadian issuer, is not an investment company, and if a majority-owned subsidiary, the parent is also a small business issuer. We are a small business issuer.

The Securities and Exchange Commission, state securities commissions and the North American Securities Administrators Association, Inc. (NASAA) have expressed an interest in adopting policies that will streamline the registration process and make it easier for a small business issuer to have access to the public capital markets.

We are also subject to the Sarbanes-Oxley Act of 2002. This Act creates a strong and independent accounting oversight board to oversee the conduct of auditors of public companies and strengthens auditor independence. It also requires steps to enhance the direct responsibility of senior members of management for financial reporting and for the quality of financial disclosures made by public companies; establishes clear statutory rules to limit, and to expose to public view, possible conflicts of interest affecting securities analysts; creates guidelines for audit committee members appointment, compensation and oversight of the work of public companies auditors; prohibits certain insider trading during pension fund blackout periods; and establishes a federal crime of securities fraud, among other provisions.

Section 14(a) of the Exchange Act requires all companies with securities registered pursuant to Section 12(g) of the Exchange Act to comply with the rules and regulations of the Securities and Exchange Commission regarding proxy solicitations, as outlined in Regulation 14A. Matters submitted to stockholders of our Company at a special or annual meeting thereof or pursuant to a written consent will require our Company to provide our stockholders with the information outlined in Schedules 14A or 14C of Regulation 14; preliminary copies of this information must be submitted to the Securities and Exchange Commission at least 10 days prior to the date that definitive copies of this information are forwarded to our stockholders.

We are also required to file annual reports on Form 10-K and quarterly reports on Form 10-Q with the Securities Exchange Commission on a regular basis, and will be required to timely disclose certain material events (e.g., changes in corporate control; acquisitions or dispositions of a significant amount of assets other than in the ordinary course of business; and bankruptcy) in a Current Report on Form 8-K.

Patents, Trademarks, Licenses, Franchises, Concessions, Royalty Agreements or Labor Contracts, including Duration

All patents and trademarks relating to acquisitions have been assigned to us. Where appropriate, we seek patent protection for inventions and developments made by our personnel and incorporated into our products or otherwise falling within our fields of interest.

We protect some of our technology as trade secrets and, where appropriate, we use trademarks or register trademarks used in connection with our products.

Patents have been issued covering the following products:

JMST chemical detectors 4 patents issued

Cryomastor ultra low temperature freezers 1 patent issued

Catalytic Converter Testing Equipment - 1 patent issued

PATENT INFORMATION

<u>Patent number</u>
<u>Title</u>
<u>Issue</u>
<u>Filing</u>
<u>Expiration</u>
6,804,976
High reliability multi-tube thermal exchange structure
Oct 19, 2004
Dec 12, 2003
Dec 12, 2023

6,530,286

Method and
apparatus for
measuring fluid flow

Mar 11, 2003

May 9, 2000

May 9, 2020

5,969,812

Spectrophotometer
apparatus with dual
concentric

beams and fiber optic
beam splitter

Oct 19, 1999

Oct 18, 1995

Oct, 18, 2015

5,699,156

Spectrophotometer
apparatus with dual
light sources and
optical paths, fiber
optic pick-up and
sample cell therefore

Dec 16, 1997

Nov 23, 1994

Dec 16, 2014

5,694,215

Optical array and
processing
electronics and
method therefore for
use in spectroscopy

Dec 2, 1997

Mar 4, 1996

Mar 4, 2016

7,283,224

Face lighting for edge
location in catalytic
converter inspection

October 16, 2007

September 30, 2004

September 30, 2024

Patent 7,283,224 is included in the assignment of assets and liabilities related to the divestiture of Image Labs and Miralogix. See Footnote 18 Subsequent Events to the financial statements.

Royalty agreements were executed with JMST, Cryometrix, All Temp and Image Labs as a condition of the companies' acquisitions. Under the terms of the royalty agreements:

JMST David Carver will receive a royalty payment on gross revenues related to revenues derived from the Carver Patents or Carver Technology. Such payments are due on revenue in excess of \$500,000 derived from products under the Carver Patents or Carver Technology. The royalty payment is 2.5% on the revenue in excess of \$500,000 and is payable quarterly. Payments are to be made in Reflect Scientific's common stock not to exceed 500,000 shares in total. New products developed from the Carver Technology are subject to a royalty of 3% of gross revenues in excess of \$100,000, with an additional 2% if gross revenues exceed \$600,000. Royalties will also be paid in our common stock annually. Common stock will be valued at \$3.00 per share for these purposes. Royalty payments are only due for years where there are valid Carver Patents.

Cryometrix The prior shareholders of Cryometrix receive a 2.5% royalty on all sales, licensing or other distributions on revenue derived from products and technology received from Cryometrix. The royalty payment is not due or payable unless and until the revenue derived from such products and technology exceeds \$3,000,000. The payment is payable in shares of Reflect Scientific's common stock not to exceed 2,000,000 shares in aggregate. Common stock will be valued at \$1.80 or market value at time of accrual which ever is greater, for these purposes. Payments are due quarterly.

All Temp The shareholders of All Temp will receive a pro-rata running royalty totaling 5% of the gross annual revenues earned from the All Temp's business unit. This revenue covers all revenues received by the All Temp subsidiary or any other business unit of Reflect Scientific which revenue is derived from products or services derived from All Temp as part of its acquisition. The royalty is payable as long as Reflect Scientific owns and operates the All Temp business provided that the royalty is not payable if the All Temp business does not have earnings of at least 10% measured by earnings before interest and taxes. The royalty is payable quarterly within 45 days following the close of each quarter. If within three years of the closing of the acquisition of All Temp, Reflect Scientific sells or transfers All Temp, its products or services, All Temp shareholders shall receive a cash payment of six hundred thousand dollars less any accumulated royalties payable.

Image Labs The shareholders of Image Labs will receive a running earnout on the gross revenues derived from products associated with Image Labs including value added re-sales and custom engineering business segments. The earnout is established as 1.25% of all gross revenues and an additional 1.25% of all revenues if the company achieves EBIT of 10%. This segment specifically excludes anything received from our Catpro product lines. The royalty is payable quarterly so long as Reflect Scientific owns the Image Labs' product line and services and as long as the business segment achieves an earnings before interest and taxes of 10% in the quarter the royalty payments are due. The royalty lasts for the life of the Image Labs' shareholders.

Research and Development Costs During the Last Two Fiscal Years

During the year ended December 31, 2009, we expended \$307,433 for research and development. During the year ended December 31, 2008, we expended \$297,402 for research and development. The majority of the research and development on our products was completed by the companies we purchased prior to our acquisition of those companies. We expect research and development cost to increase in the future with our ownership of the new companies and product lines.

Employees

As of March 30, 2010, subsequent to the balance sheet date, we had 5 employees on a full-time basis and 4 part time employees. None of our employees are represented under a collective bargaining agreement. We believe our relations with our employees to be good.

Reports to Security Holders

You may read and copy any materials that we file with the Securities and Exchange Commission at the Securities and Exchange Commission's Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may also find all of the reports that we have filed electronically with the Securities and Exchange Commission at their Internet site

www.sec.gov.

Item 1a. Risk Factors

Not applicable for Small Business Issuers

Item 2. Description of Property

Reflect Scientific operates out of two facilities.

Orem, Utah - This facility is a warehouse, manufacturing and office facility with 6,000 square feet of space; we lease this facility at \$3,800 per month, with the lease term expiring on November 30, 2014.

Bozeman, Montana - This facility is a warehouse, manufacturing and office facility with 9,140 square feet of space; we lease this facility at \$9,801 per month, with the lease term expiring on May 31, 2011. Subsequent to year end the lease was assumed by the purchasing entity.

Item 3. Legal Proceedings

On October 16, 2009, the Company filed a complaint in the Third District Court in the State of Utah in which it seeks the return of the stock issued for the acquisition of Cryomastor. The action alleges misrepresentation and, in addition to the return of the stock, seeks monetary damages

Item 4. Submission of Matters to a Vote of Security Holders

No matter was submitted to a vote of our security holders during the period covered by this Annual Report or during the previous two fiscal years.

PART II

Item 5. Market for Common Equity and Related Stockholder Matters and Small Business Issuer Purchases of Equity Securities.

Market Information

Since July 6, 2005, our common stock has been listed under the symbol `RSCF` on the OTCBB. Prior to July 6, 2005, our stock traded under the symbol `COLH` since its initial listing on May 24, 2001. The following table represents the high and low per share bid information for our common stock for each quarterly period in fiscal 2009, 2008 and 2007. Such high and low bid information reflects inter-dealer quotes, without retail mark-up, mark-down or commissions and may not represent actual transactions.

2009

2008

2007

High

Low

High

Low

High

Low

Quarter
ended
December
31

\$ 0.24

\$

0.12

\$	
	0.20
\$	
	0.40
\$	
	1.95
\$	
	1.20
	Quarter ended September 30
\$	0.24
\$	
	0.14
\$	
	0.77
\$	
	.044
\$	
	1.88
\$	
	1.12
	Quarter ended June 30
\$	0.25
	\$

	0.15
\$	
	0.95
\$	
	0.70
\$	
	1.75
\$	
	0.99
Quarter ended March 31	
\$	0.25
	\$
	0.10
\$	
	1.30
\$	
	0.70
\$	
	1.15
\$	
	0.92

As of March 30, 2020, there were 35,221,650 shares of our common stock outstanding. On March 30, 2010, the high and low bid price for our common stock was \$0.11 and \$0.11, respectively.

Holders

The number of record holders of our common stock as of March 30, 2010, was approximately 137; this number does not include an indeterminate number of stockholders whose shares may be held by brokers in street name.

Dividends

We have not declared any cash dividends with respect to our common stock, and do not intend to declare dividends in the foreseeable future. Our future dividend policy cannot be ascertained with any certainty. There are no material restrictions limiting, or that are likely to limit, our ability to pay dividends on our securities.

Securities Authorized for Issuance under Equity Compensation Plans

Plan Category

Number of Securities to be issued upon exercise of outstanding options, warrants and rights

Weighted-average exercise price of outstanding options, warrants and rights

Number of securities
remaining available for
future issuance under
equity compensation plans
excluding securities
reflected in column (a)

(a)

(b)

(c)

Equity compensation plans
approved by security
holders

10,243,320

\$0.71

1,756,680

Equity compensation plans
not approved by security
holders

4,151,895

\$0.90

None

Total

14,395,215

\$0.62

1,756,680

Recent Sales of Unregistered Securities

On June 29, 2008, Reflect Scientific pursuant to the securities purchase agreement sold to five institutional investors convertible debentures in the aggregate principal amount of \$2,500,000 and stock purchase warrants exercisable over a five year period for 3,846,154 shares of common stock (the Warrants) in a private placement. All purchasers are accredited investors and a form D was filed covering this transaction.

We issued all of these securities to persons who were accredited investors or sophisticated investors as those terms are defined in Regulation D of the Securities and Exchange Commission; and each such investor had prior access to all material information about us. We believe that the offer and sale of these securities were exempt from the registration requirements of the Securities Act, pursuant to Sections 4(2) and 4(6) thereof, and Rule 506 of Regulation D of the Securities and Exchange Commission. Sales to accredited investors are preempted from state regulation.

During the year ended December 31, 2009, we issued a net of 719,040 shares of common stock. Of this amount, 320,450 shares were issued in payment of interest on our debentures, 273,590 shares were issued in the conversion of debentures, 600,000 shares were issued for consulting services, and 25,000 shares were issued to a former employee, for a total of 1,219,040 shares issued. An original shareholder of All Temp Engineering returned 500,000 shares of stock issued to him in the All Temp acquisition transaction, which shares were cancelled, resulting in the net new issuance of 719,040 shares in 2009.

During the year ended December 31, 2008, 402,072 shares of common stock were issued. Of that total amount, 212,307 shares were issued for the conversion of debentures and 189,765 shares were issued in payment of interest to the debenture holders.

Use of Proceeds of Registered Securities

There were no proceeds received during the calendar year ended December 31, 2009, from the sale of registered securities.

Purchases of Equity Securities by Us and Affiliated Purchasers

There were no purchases of our equity securities by us or any of our affiliates during the year ended December 31, 2009.

Item 6. Select Financial Data

As a smaller reporting company, we are not required to provide information under this item.

Item 7. Management's Discussion and Analysis or Plan of Operation

This periodic report contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the Plan of Operations provided below, including information regarding the Company's financial condition, results of operations, business strategies, operating efficiencies or synergies, competitive positions, growth opportunities, and the plans and objectives of management. The statements made as part of the Plan of Operations that are not historical facts are hereby identified as "forward-looking statements."

The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read in conjunction with the financial statements and notes included in this report as Part II, Item 8.

Critical Accounting Policies and Estimates

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited Condensed Consolidated Financial Statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions. Reflect Scientific believes there have been no significant changes during the year ended December 31, 2009.

Reflect Scientific's accounting policies are more fully described in Note 1 of the consolidated financial statements. As discussed in Note 1, the preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about the future

events that affect the amounts reported in the consolidated financial statements and the accompanying notes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual differences could differ from these estimates under different assumptions or conditions. Reflect Scientific believes that the following addresses Reflect Scientific's most critical accounting policies.

We recognize revenue in accordance with Securities and Exchange Commission Staff Accounting Bulletin No. 104, Revenue Recognition (SAB 104). Under SAB 104, revenue is recognized at the point of passage to the customer of title and risk of loss, when there is persuasive evidence of an arrangement, the sales price is determinable, and collection of the resulting receivable is reasonably assured. We recognize revenue as services are provided with specific long lead time orders.

Our allowance for doubtful accounts is maintained to provide for losses arising from customers' inability to make required payments. If there is deterioration of our customers' credit worthiness and/or there is an increase in the length of time that the receivables are past due greater than the historical assumptions used, additional allowances may be required.

We account for income taxes in accordance with Statement of Financial Accounting Standards Board Accounting Codification (ASC) 740, Income Taxes. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets will be reflected on the balance sheet when it is determined that it is more likely than not that the asset will be realized.

Overview

The year ended December 31, 2009 has been a difficult year for the Company. Historically, significant portions of our revenue come from the manufacture and sale of capital equipment purchased by our customers. The economic climate the past year has caused many of these customers to defer, significantly reduce, or eliminate altogether their capital budget spending. The reduced level of capital spending has had a significant impact on our sales for 2009. Capital markets have also been tight, with the result that we were unable to secure funding with which to retire our debentures which matured June 30, 2009, and we are currently in default on that indebtedness. Due to the historical losses and the default status on our debentures, our accountants have expressed substantial doubt about our ability to continue as a going concern.

The Company has been proactive in making those business decisions which it believes will enable it to carry out its business plan. Significant cost reduction measures have been implemented, facilities consolidated and personnel reductions made. We have reached a settlement agreement with the majority holder of our debentures whereby, upon the payment of a portion of the principal, the remaining principal and penalty amount will be converted into common stock of the company. Our ability to execute this agreement is dependent upon the obtaining of additional funding at terms that are acceptable. While we have confidence that we will obtain the required financing, we cannot assure you

that it will be made available. If we are unable to secure financing, our ability to proceed with and implement our intended business plan will be negatively impacted.

Financial Position

The table below presents a summary of our consolidated balance sheets at December 31, 2009 and 2008:

**SUMMARY OF
BALANCE
SHEET
INFORMATION**

Year ended
Dec. 31, 2009

Year ended
Dec 31, 2008

Increase

(Decrease)

Cash and cash
equivalents

\$ 165,633

\$ 447,037

Edgar Filing: REFLECT SCIENTIFIC INC - Form 10-K

\$ (281,404)

Total current assets

1,362,431

3,116,193

(1,753,762)

Total assets

6,153,459

9,235,509

(3,082,050)

Total current
liabilities

3,984,372

2,852,914

1,131,458

Accumulated
deficit

(15,656,425)

(10,774,547)

(4,881,878)

Total stockholders
equity

\$ 2,159,372

\$ 6,363,089

\$ (4,203,717)

Edgar Filing: REFLECT SCIENTIFIC INC - Form 10-K

We had \$165,633 in cash as of December 31, 2009, a decrease of \$281,404 from December 31, 2008. We had a working capital deficit of \$2,619,541 at December 31, 2009, compared to positive working capital of \$263,279. This change results from the re-classification of the debentures from a long-term liability to a current liability.

Contractual Obligations

The Company leases office/warehouse space in both Utah and Montana. In addition, it has a lease on a vehicle. The following summarizes future minimum lease payments under the operating leases at December 31, 2009:

Year Ending	Minimum
<u>November 30,</u>	<u>Lease Payments</u>
2010	\$ 174,312
2011	
124,244	
2012	
52,528	
2013	
54,366	
2014	
<u>51,430</u>	
	<u>\$ 456,880</u>

Results of Operations

December 31, 2009 and 2008

The following table summarizes revenue, cost of goods sold, and operating expenses for the years ended December 31, 2009 and 2008:

Edgar Filing: REFLECT SCIENTIFIC INC - Form 10-K

Year Ended
November 30,
2009

Year Ended
November 30,
2008

Increase
(Decrease)

Revenue

\$5,658,125

\$ 10,126,805

\$(4,468,680)

Cost of Goods
Sold

3,441,336

5,500,694

(2,059,358)

Gross Profit

2,216,789

4,626,111

(2,409,322)

Salaries and
wages

2,348,326

1,885,673

462,653

Rent expense

305,055

277,463

27,592

Research and
development
expense

307,433

297,402

10,031

General and
administrative
expense

1,725,203

2,998,008

(975,403)

Total
operating
expenses

4,686,017

5,161,144

(475,127)

Net loss

\$(4,881,878)

\$(2,164,396)

\$(2,715,082)

Revenue saw a significant reduction for the period ended December 31, 2009 as compared to December 31, 2008. A significant part of our sales come from the manufacture and installation of capital equipment. With the downturn in the economy, many companies have elected to defer or cancel capital investments until the economy recovers.

Our cost of goods decreased in the period ending December 31, 2009, as compared to December 31, 2008, due primarily to the reduced levels of sales. The percentage on gross margins decreased to 39% in 2009, a 15% decrease over the 54% margins realized in 2008. Our gross margin percent is heavily influenced by the sales mix. Also, some of the allocated costs related to cost of sales are fixed costs and are not sales volume dependent.

In the early part of 2009, significant investment was made in sales personnel to increase awareness of our products and generate additional sales. When it became apparent that the business climate would not support the hoped for sales increases, reductions were made, which will reduce salaries in future periods reported. Management made the decision to scale back the refrigeration service business, using contractors rather than maintaining employees, service vehicles, and the related expenses. Savings realized from this change will be reflected in future periods.

General and administrative expenses decreased to \$2,032,636 during the year ended December 31, 2009, from \$2,998,008 during the year ended December 31, 2008. This reduction results in part from efficiency measures implemented by management during 2009. Expense reductions continue to be made, and it is anticipated that the expense level in future periods will continue to decline as we make our operations more efficient and cost effective.

The net loss of \$4,881,878 for the year ended December 31, 2009 contains the following one-time expenses:

Penalty on debenture default

\$ 690,000

Impairment of long-lived asset charges

708,265

Stock-based compensation charges

422,804

Total

\$1,821,069

The recording of these charges made a significant impact on the results for the year ended December 31, 2009, and make it difficult to compare the 2009 results against the prior year.

Seasonality and Cyclicity

We do not believe our business is cyclical.

Liquidity and Capital Resources

Our cash resources at December 31, 2009, were \$165,633, with accounts receivable of \$522,921 and inventory of \$591,672. We have relied on revenues and sales of equity and debt securities for cash resources. As a result of the decreases in cash, accounts receivables, and inventories, coupled with increases in accounts payable, interest payable, and the penalty on the debenture default, we had negative working capital of \$2,619,541 at December 31, 2009. This compares to positive working capital of \$263,279 at December 31, 2008.

In 2009, net cash used by operating activities was \$275,130 in cash as compared to \$286,105 in 2008. We are hopeful that in 2010, with the raising of additional capital and the benefit of continued cost reductions, we will be able to further reduce our cash requirements.

We will continue to focus our efforts on our core business activities while pursuing capital resources and evaluating potential future acquisitions.

Off-Balance Sheet Arrangements

We lease office and warehouse space under non-cancelable operating leases in both Utah and Montana. Future minimum lease payments under the operating lease at December 31, 2009 are \$260,717 for the Utah facility and \$190,339 for the Montana facility. In addition, we have an automobile lease with future minimum lease payments of \$5,825.

Item 7a. Quantitative and Qualitative Disclosures About Market Risk

Not applicable to Small Business Issuers

Item 8. Financial Statements

The financial statements of the Company are set forth immediately following the signature page to this Form 10-K.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

We had no disagreements on accounting and financial disclosures with our accounting firm during the reporting periods covered by this Annual Report.

Item 9A(T). Controls and Procedures

As of the end of the period covered by this Annual Report, we conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of our disclosure controls and

procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act). Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that information required to be disclosed is recorded, processed, summarized and reported within the specified periods and is accumulated and communicated to management, including our President and Chief Financial Officer, to allow for timely decisions regarding required disclosure of material information required to be included in our periodic Securities and Exchange Commission reports. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective to a reasonable assurance level of achieving such objectives. However, it should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

Management's Annual Report on Internal Control over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes of accounting principles generally accepted in the United States.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our internal control over financial reporting as of December 31, 2009. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework. Based on this evaluation, our management concluded that, as of December 31, 2009, our internal control over financial reporting was effective.

Inherent Limitations Over Internal Controls

Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations, including the possibility of human error and circumvention by collusion or overriding of controls. Accordingly, even an effective internal control system may not prevent or detect material misstatements on a timely basis. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

Changes in internal control over financial reporting

We have made no change in our internal control over financial reporting during the last fiscal year that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Attestation Report of the Registered Public Accounting Firm

This annual report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by our

independent registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management's report in this annual report on Form 10-K.

Item 9(B). Other Information.

None; not applicable.

PART III

Item 10. Directors, Executive Officers, Promoters and Control Persons; Compliance with Section 16(a) of the Exchange Act

Identification of Directors and Executive Officers

The following table sets forth the names of all of our current directors and executive officers. These persons will serve until the next annual meeting of the stockholders or until their successors are elected or appointed and qualified, or their prior resignation or termination.

Name
Positions Held
Date of Election or Designation
Date of Termination or Resignation

Kim Boyce

President &

12/03

*

Director

12/03

*

Tom Tait

Vice President &

01/05

*

Director

01/05

*

Kevin Cooksy

Secretary

01/05

*

Treasurer

01/05

*

Craig D. Morrison

Director

1/05

*

Keith L. Merrell

Chief Financial Officer

10/09

*

* These persons presently serve in the capacities indicated.

Business Experience

Kim Boyce - CEO, Director

Mr. Boyce, 55, is the founder of Reflect Scientific and serves as President, Chief Executive Officer and Chairman of our Board of Directors. Mr. Boyce has over thirty years of experience in manufacturing, sales, distribution and management of scientific products related to companies in the chemical analysis, semiconductor fabrication and optics industries. His responsibilities have included serving as a Western Regional Sales Manager, OEM Special Accounts Manager, Plant Operations Manager and various other senior management positions within these industries.

Thomas Tait - Vice President, Director

Mr. Tait, 53, serves as Vice President. Mr. Tait brings experience with accelerated product development, lean process management tools, strategic market analysis, and acquisition integration. Mr. Tait joined us from Danaher Company where he was a Business Manager over a \$120 million in sales product line. Prior assignments have included General Manager of HyperQuan Inc., Product Manager J&W Scientific and Project Manager Varian Inc. He also co-founded ChiraTech Inc, a high technology Company that was sold to Thermo Electron Corporation. Mr. Tait holds an MBA in Technology Management from the University of Phoenix and a BS in Chemistry from Clarkson University. He also holds patents in Optics and MEMS technologies.

Kevin Cooksy - Secretary / Treasurer

Mr. Cooksy, 47, serves as the company's secretary and treasurer with general responsibility for financial, legal and administrative matters. Over the last twenty years, Mr. Cooksy has served in corporate legal, corporate development and finance capacities with public and private emerging technology organizations in the commercial, academic and government sectors. He is an Honors Research Program graduate in Analytical Chemistry from Northern Illinois University and received his MBA (Finance) from The Lake Forest College Graduate School of Management (magna cum laude) and a Juris Doctor degree from the McGeorge School of Law, University of the Pacific.

Craig Morrison, MD- Board Member

Dr. Morrison, 66, serves on the Board of Directors. Dr. Morrison is a surgeon practicing in the State of Utah. He has provided his medical expertise and is one of the pioneering shareholders in the finance and development of Sanguine Corporation. Sanguine is a company focused on developing synthetic alternatives to blood. Dr. Morrison will support the activities of the Board lending his knowledge of startup operations gained through his long experience and development of Sanguine.

Keith Merrell - Chief Financial Officer

Mr. Merrell, 64, serves as our Chief Financial Officer, Treasurer and General Manager. Mr. Merrell draws on over 30 years of accounting experience to manage all of our accounting functions and to interface with our independent public accountants. He spent two years in the field of public accounting, and served as Chief Financial Officer or Controller of five companies prior to joining us. His business career also includes extensive experience in management, sales and marketing, consulting, and merger and acquisition work. He graduated from Arizona State University with a B.S. degree in Accounting.

Significant Employees

There are no employees who are not executive officers who are expected to make a significant contribution to our Company's business.

Family Relationships

There are no family relationships between our officers and directors.

Involvement in Certain Legal Proceedings

During the past five years, no director, person nominated to become a director, executive officer, promoter or control person of our Company:

(1) was a general partner or executive officer of any business against which any bankruptcy petition was filed, either at the time of the bankruptcy or two years prior to that time;

(2) was convicted in a criminal proceeding or named subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);

(3) was subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent

jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; or

(4) was found by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

Compliance with Section 16(a) of the Exchange Act

Section 16(a) of the Exchange Act requires that our executive officers and directors and persons who beneficially own more than 10% of our common stock, file initial reports of stock ownership and reports of changes in stock ownership with the Securities and Exchange Commission. Officers, directors, and greater than 10% owners are required by applicable regulations to furnish our Company with copies of all Section 16(a) forms that they file.

Based solely on a review of the copies of such forms furnished to us or written representations from certain persons, we believe that during our calendar year ended December 31, 2009, all filing requirements applicable to our officers, directors and 10% stockholders were met by such persons.

Code of Ethics

We have adopted a Code of Ethics that applies to all of our directors and executive officers serving in any capacity for our Company, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions, which Code of Ethics was attached to our Form 10-K annual Report for the year ended December 31, 2003. See Part III, Item 13.

Nominating Committee

We have not established a Nominating and Corporate Governance Committee because we believe that the three members currently comprising our Board of Directors are able to effectively manage the issues normally considered by a Nominating and Corporate Governance Committee.

Audit Committee

Due to the size and status of our Company we have no Audit Committee, and are not required to have an audit committee. We do not believe the lack of an Audit Committee will have any adverse effect on our financial statements, based upon our current operations. We will assess whether an audit committee may be necessary in the future.

Item 11. Executive Compensation

The following table sets forth the aggregate compensation paid by us for services rendered during the periods indicated:

SUMMARY COMPENSATION TABLE

Name and
Principal
Position

(a)

Year

(b)

Salary

(\$)

(c)

Bonus

(\$)

(d)

Stock Awards

(\$)

(e)

Option
Awards

(\$)

(f)

Non-Equity
Incentive Plan
Compensation

(\$)

(g)

Nonqualified
Deferred
Compensation

(\$)

(h)

All Other
Compensation

(\$)

(i)

Total

Earnings

(\$)

(j)

Kim Boyce
President &
Director

12/31/09

12/31/08

12/31/07

\$105,000

\$105,000

\$105,000

0

0

0

0

0

0

\$391,404

0

3,214,456

0

0

0

0

0

0

0

0

0

\$496,404

\$105,000

\$3,319,456

Tom Tait VP
& Director

12/31/09

12/31/08

12/31/07

\$70,000

\$70,000

\$63,077

0

0

0

0

0

0

\$16,600

0

\$139,101

0

0

0

0

0

0

0

0

0

\$86,600

\$70,000

\$202,178

Kevin Cooksy

Sec/Treas

12/31/09

12/31/08

12/31/07

0

0

0

0

0

0

0

0

0

\$830

0

0

0

0

0

0

0

0

0

0

0

\$830

0

Keith Merrell,
CFO (1)

12/31/09

\$8,989

0

0

\$1,660

0

0

0

\$10,649

David Strate,
CFO (2)

12/31/09

12/31/08

12/31/07

\$65,396

\$85,000

\$21,250

0

0

0

0

0

Name

Number of securities
underlying unexercised
Options (#) Exercisable

Number of Securities
Underlying Unexercised
Options (#) Unexercisable

Equity Incentive Plan
Awards: Number of
Securities Underlying
Unexercised Unearned
Options (#)

Option Exercise Price (\$)

Option Expiration Date

Number of Shares or Units
of Stock That Have Not
Vested (#)

Market Value of Shares or
Units of Stock That Have
Not Vested (\$)

Equity Incentive Plan
Awards: Number of
Unearned Shares Units or
Other Rights That Have Not
Vested (#)

Equity Incentive Plan
Awards Market or Payout
Value of Unearned Shares,
Units or Other Rights That
Have Not Vested (#)

Kim Boyce

4,800,000

4,800,000

4,800,000

4,800,000

None

None

\$1.32

\$0.132

12/31/2012

12/30/2019

None

None

None

None

None

None

None

None

Tom Tait

200,000

200,000

200,000

200,000

None

None

\$1.20

\$0.12

12/31/2012

12/30/2019

None

None

None

None

None

None

None

None

Kevin Cooksy

10,000

10,000

None

\$0.12

12/30/2019

None

None
None
None
Keith Merrell
20,000
20,000
None
\$0.12
12/30/2019
None
None
None
None

The fair market value of the options issued above is \$3,764,051. This value was calculated using the Black Scholes pricing model for Options and Warrants.

Compensation of Directors

Name
Fees Earned or Paid in Cash (\$)
Stock Awards (\$)
Option Awards (\$)
Non-Equity Incentive Plan Compensation

(\$)

Nonqualified
Deferred
Compensation
Earnings (\$)

All Other
Compensation
(\$)

Total (\$)

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

None

None

None

None

None

None

None

None

Item 12. Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners

The following table sets forth, as of March 30, 2010, the names, addresses and number of shares of common stock beneficially owned by all persons known to the management of Reflect Scientific to be beneficial owners of more than 5% of the outstanding shares of common stock, and the names and number of shares beneficially owned by all directors of Reflect Scientific and all executive officers and directors of Reflect Scientific as a group (except as indicated, each beneficial owner listed exercises sole voting power and sole dispositive power over the shares beneficially owned).

For purposes of this table, information as to the beneficial ownership of shares of common stock is determined in accordance with the rules of the Securities and Exchange Commission and includes general voting power and/or investment power with respect to securities. Except as otherwise indicated, all shares of our common stock are beneficially owned, and sole investment and voting power is held, by the person named. For purposes of this table, a person or group of persons is deemed to have "beneficial ownership" of any shares of common stock, which such person has the right to acquire within 60 days after the date hereof. The inclusion herein of such shares listed beneficially owned does not constitute an admission of beneficial ownership.

All percentages are calculated based upon a total number of 35,221,650 shares of common stock outstanding as of March 30, 2010, plus, in the case of the individual or entity for which the calculation is made, that number of options or warrants owned by such individual or entity that are currently exercisable or exercisable within 60 days.

Amount and Nature of

Percentage of Outstanding

Title of Class

Name and Address of Beneficial
Owner

Beneficial Owner

Common stock

Principal Shareholders

Common Stock

Kim Boyce (1)

1270 South 1380 West

Orem, Utah 84058

26,518,250

59.16%

Common Stock

Dain Family Revocable Trust

4057 Cienega Road

Hollister, California 95023

2,030,000

5.76%

Common Stock

Nicholas J. Henneman

P.O. Box 1175

5885 Diablo Hills Road

Tres Pinos, California 95075-1175

1,940,000

5.51%

Officers and Directors

Common Stock

Kim Boyce

26,518,250

59.16%

Common Stock

Tom Tait (2)

561,000

1.57%

Common Stock

Keith Merrell (3)

45,000

.12%

Common Stock

Kevin Cooksy (4)

60,000

.17%

Common Stock

Craig D. Morrison, M.D.

210,000

5.96%

All directors and executive officers
of the Company as a group (Five
individuals)

27,394,250

=====

60.54%

=====

(1) Includes 4,800,000 shares issuable upon exercise of stock options with an exercise price of \$1.32 per share and 4,800,000 shares issuable upon exercise of stock options with an exercise price of \$0.132 per share.

(2) Includes 200,000 shares issuable upon exercise of stock options with an exercise price of \$1.20 per share and 200,000 shares issuable upon exercise of stock options with an exercise price of \$0.12 per share.

(3) Includes 25,000 shares beneficially owned through an IRA and 20,000 shares issuable upon exercise of stock options with an exercise price of \$0.12 per share.

(4) Includes 10,000 shares issuable upon exercise of stock options with an exercise price of \$0.12 per share.

Changes in Control

There are no current or planned transactions that would or are expected to result in a change of control of our Company.

Securities Authorized for Issuance under Equity Compensation Plans

Plan Category
Number of Securities to be issued upon exercise of outstanding options, warrants and rights
Weighted-average exercise price of outstanding options, warrants and rights
Number of securities remaining available for future issuance under equity compensation plans excluding securities reflected in column (a)
(a)
(b)
(c)
Equity compensation plans approved by security holders
10,243,320
\$0.71
1,756,680

Equity compensation plans
not approved by security
holders

4,151,895

\$0.90

None

Total

14,395,215

=====

\$0.62

1,756,680

=====

Item 13. Certain Relationships and Related Transactions

Transactions with Related Persons

There were no material transactions, or series of similar transactions, during our Company's last fiscal year, or any currently proposed transactions, or series of similar transactions, to which our Company or any of our subsidiaries was or is to be a party, in which the amount involved exceeded the lesser of \$120,000 or one percent of the average of our total assets at year-end for the last three completed fiscal years and in which any director, executive officer or any security holder who is known to us to own of record or beneficially more than five percent of any class of our common stock, or any member of the immediate family of any of the foregoing persons, had an interest.

Parents of the Issuer

None; however Kim Boyce, our President and a director, may be deemed to be our Parent by virtue of his substantial shareholdings in our Company.

Transactions with Promoters and control persons

There were no material transactions, or series of similar transactions, during our Company's last five fiscal years, or any currently proposed transactions, or series of similar transactions, to which we or any of our subsidiaries was or is to be a party, in which the amount involved exceeded \$120,000 and in which any promoter or founder of ours or any member of the immediate family of any of the foregoing persons, had an interest.

Item 14. Principal Accounting Fees and Services

The Following is a summary of the fees billed to us by our principal accountants during the fiscal years ended December 31, 2009 and 2008:

**Fee
Category**

2009

2008

Audit Fees

\$

72,862

\$

68,507

Audit-related
Fees

\$

0

\$

0

Tax Fees

\$

0

\$

0

All Other
Fees

\$

0

\$

0

Total Fees

\$

72,862

\$

68,507

Audit Fees - Consists of fees for professional services rendered by our principal accountants for the audit of our annual financial statements and review of the financial statements included in our Forms 10-Q or services that are normally provided

21

by our principal accountants in connection with statutory and regulatory filings or engagements.

Audit-related Fees - Consists of fees for assurance and related services by our principal accountants that are reasonably related to the performance of the audit or review of our financial statements and are not reported under **Audit fees**.

Tax Fees - Consists of fees for professional services rendered by our principal accountants for tax compliance, tax advice and tax planning.

All Other Fees - Consists of fees for products and services provided by our principal accountants, other than the services reported under **Audit fees**, **Audit-related fees**, and **Tax fees** above.

Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors

We do not have an Audit Committee; therefore, there is no Audit Committee policy in this regard. However, we do require approval in advance of the performance of professional services to be provided to us by our principal accountant. Additionally, all services rendered by our principal accountant are performed pursuant to a written engagement letter between us and the principal accountant.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

Item 15. Exhibits

Exhibits

Exhibit No.

Title of Document

Location if other than attached hereto

3.1

Articles of Incorporation

10-SB Registration Statement*

3.2

Articles of Amendment to Articles of Incorporation

10-SB Registration Statement*

3.3

By-Laws

10-SB Registration Statement*

3.4

Articles of Amendment to Articles of Incorporation

8-K Current Report dated December 31, 2003*

3.5

Articles of Amendment to Articles of Incorporation

8-K Current Report dated December 31, 2003*

3.6

Articles of Amendment

September 30, 2004 10-QSB Quarterly Report*

3.7

Edgar Filing: REFLECT SCIENTIFIC INC - Form 10-K

By-Laws Amendment

September 30, 2004 10-QSB Quarterly Report*

4.1

Debenture

8-K Current Report dated June 29, 2008*

4.2

Form of Purchasers Warrant

8-K Current Report dated June 29, 2008*

4.3

Registration Rights Agreement

8-K Current Report dated June 29, 2008*

4.4

Form of Placement Agreement

8-K Current Report dated June 29, 2008*

5.1

Legal Opinion and Consent

This Filing

10.1

Securities Purchase Agreement

8-K Current Report dated June 29, 2008*

10.2

Placement Agent Agreement

8-K Current Report dated June 29, 2008*

10.3

JMST Purchase Agreement

8-k Current Report dated April 4, 2006*

Edgar Filing: REFLECT SCIENTIFIC INC - Form 10-K

10.4

Cryomastor Merger Agreement

8-K Current Report dated April 19, 2006*

10.5

Image Labs Merger Agreement

8-K Current Report dated November 15, 2006*

10.6

All Temp Merger Agreement

8-K Current Report dated November 17, 2006*

14

Code of Ethics

December 31, 2003 10-K Annual Report*

21

Subsidiaries of the Company

December 31, 2006 10-K Annual Report*

31.1

302 Certification of Kim Boyce

This Filing

31.2

302 Certification of David Strate

This Filing

32

906 Certifications

This Filing

* Previously filed with the Securities and Exchange Commission in the form indicated and incorporated by reference

Additional Exhibits Incorporated by Reference

*

Reflect California Reorganization

8-K Current Report dated December 31, 2003

*

JMST Acquisition

8-K Current Report dated April 4, 2006

*

Cryomastor Reorganization

8-K Current Report dated June 27, 2006

*

Image Labs Merger Agreement Signing

8-K Current Report dated November 15, 2006

*

All Temp Merger Agreement Signing

8-K Current Report dated November 17, 2006

*

All Temp Merger Agreement Closing

8-KA Current Report dated November 17, 2006

*

Image Labs Merger Agreement Closing

8-KA Current Report dated November 15, 2006

*

Debenture Placement

* Previously filed and incorporated by reference.

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act, the Company caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

REFLECT SCIENTIFIC, INC.

Date:

03/31/2010

By:

/s/Kim Boyce

*Kim Boyce, Chief Executive Officer and
Director*

Date:

03/31/2010

By:

/s/Keith Merrell

*Keith Merrell, Chief Financial Officer
(Principal Accounting Officer)*

In accordance with the Securities Exchange Act, this Report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated:

REFLECT SCIENTIFIC, INC.

Date:

03/31/2010

By:

/s/Kim Boyce

Kim Boyce, CEO and Director

Date:

03/31/2010

By:

/s/Tom Tait

Tom Tait, Vice President and Director

Date:

03/31/2010

By:

/s/Kevin Cooksy

*Kevin Cooksy, Secretary/Treasurer and
Director*

REFLECT SCIENTIFIC, INC. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2009

CONTENTS

Reports of Independent Registered Public Accounting Firms	27
Consolidated Balance Sheets	28
Consolidated Statements of Operations	29
Consolidated Statements of Shareholders' Equity	31
Consolidated Statements of Cash Flows	32
Notes to the Consolidated Financial Statements	95

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Shareholders of

Reflect Scientific, Inc. and Subsidiaries

Orem, Utah

We have audited the accompanying consolidated balance sheets of Reflect Scientific, Inc. and Subsidiaries as of December 31, 2009 and 2008, and the related consolidated statements of operations, stockholder's equity and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audit in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company has determined that it is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the Company's internal controls over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Reflect Scientific, Inc. and Subsidiaries as of December 31, 2009 and 2008, and the results of their operations and their cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has experienced recurring losses from

operations and negative operating cash flows from operations. The Company is in default on its debentures. These factors raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Mantyla McReynolds, LLC

Mantyla McReynolds, LLC

Salt Lake City, Utah

March 31, 2010

REFLECT SCIENTIFIC, INC. AND SUBSIDIARIES

Consolidated Balance Sheet

ASSETS

December
31,
2009

December
31,
2008

CURRENT
ASSETS

Cash
\$
165,633
\$
447,037

Accounts
receivable,
net

522,921

1,005,864

O t h e r
receivables

235

28,818

Inventory

591,672

765,589

Cost and
estimated
earnings in
excess of
contract
billings

43,635

692,905

Prepaid
assets

38,335

175,980

T o t a l
C u r r e n t
A s s e t s

1,362,431

3,116,193

F I X E D
A S S E T S ,
N E T

419,822

589,298

**O T H E R
A S S E T S**

**Intangible
assets, net**

3,708,602

4,502,203

Goodwill

652,149

970,648

Prepaid
assets
long-term

-

27,223

Deferred
tax asset

-

-

Deposits

10,455

29,944

Total Other
Assets

4,371,206

5,530,018

T O T A L
A S S E T S

\$

6,153,459

\$

9,235,509

The accompanying notes are an integral part of these consolidated financial statements.

REFLECT SCIENTIFIC, INC. AND SUBSIDIARIES

Consolidated Balance Sheet (Continued)

LIABILITIES AND SHAREHOLDERS' EQUITY

December 31,
2009

December 31,
2008

**C U R R E N T
LIABILITIES**

Accounts payable

\$

507,794

\$

584,638

Short-term lines of
credit

141,474

141,366

Convertible
debenture, net of
discount

2,925,000

1,752,750

Royalty payable

22,542

73,550

Contract billings in
excess cost and
estimated earnings

-

164,761

Capital leases
short term portion

9,791

20,641

Interest payable

263,250

70,110

Accrued expenses

93,721

44,698

Loan from related party

18,000

-

Income taxes payable

2,800

400

Total Current
Liabilities

3,984,372

2,852,914

NON-CURRENT
LIABILITIES

Capital leases
long-term portion

9,715

19,506

T o t a l
N o n - C u r r e n t
L i a b i l i t i e s

9,715

19,506

Total Liabilities

3,994,087

2,872,420

SHAREHOLDERS
EQUITY

Preferred stock,
\$0.01 per value,
authorized
5,000,000 shares;
no shares issued and
outstanding

-

-

Common stock,
\$0.01 par value,
authorized
100,000,000
shares; 35,221,650
and 34,502,610
shares issued and
outstanding
respectively

352,217

345,026

Additional paid in
capital

17,463,580

16,792,610

Accumulated deficit

(15,656,425)

(10,774,547)

Total Shareholders
Equity

2,159,372

6,363,089

TOTAL
LIABILITIES AND
SHAREHOLDERS
EQUITY

\$

6,153,459

\$

9,235,509

REFLECT SCIENTIFIC, INC. AND SUBSIDIARIES

Consolidated Statements of Shareholders' Equity

Shares

Amount

Shares

Amount

Additional
Paid-In
Capital

Stock
Subscription

Accumulated
Deficit

Edgar Filing: REFLECT SCIENTIFIC INC - Form 10-K

Balance,
December 31,
2007

-

\$ -

34,100,538

\$341,006

\$16,512,094

\$ -

\$(8,610,151)

Partial
conversion of
convertible
debenture

-

-

94,615

946

60,554

-

-

Partial
conversion of
convertible
debenture

-

-

20,769

208

13,292

118

-
-
Common stock issued for payment of interest
-
-
105,230
1,052
72,609
-
-
Partial conversion of convertible debenture
50,000
500
32,000
-
-
Options issued
-
-
-

-
29,943

-
-
Partial
conversion of
convertible
debenture

-
-
46,923
469
30,031

Common
stock issued
for payment
of interest

-
-
5,727
57
4,352

-
-
Shareholder
Contribution

-
-
-
3,500
-
-
Common stock issued for payment of interest
-
-
78,808
788
30,735
Shareholder Contribution
-
-
-
-
3,500
-
-
Net loss for the year ended
121

December 31,
2008

-
-
-
-
-

(2,164,396)

Balance,
December 31,
2008

-

\$ -

34,502,610

\$345,026

\$16,792,610

\$ -

\$(10,774,547)

Common
stock issued
for payment
of interest

-

-

80,045

122

800

19,211

-

-

Common
stock issued
for payment
of interest

-

-

135,462

1,355

23,029

-

-

Partial
conversion of

123

convertible
debenture

-

-

56,923

569

36,431

-

-

Common
stock issued
for consulting
services

-

-

100,000

1,000

124

16,000

-

-

Common
stock issued
for payment
of interest

-

-

86,693

867

16,472

-

-

Partial
conversion of
convertible
debenture

-
-
216,667
2,167
62,833
-
-
Common
stock issued
for payment
of interest
-
-
18,250
183
2,190
126

-
-
Common stock issued for consulting services
-
-
300,000
3,000
36,000
-
-
Common stock issued to former employee
-

-

25,000

250

3,000

-

-

Common
stock issued
for consulting
services

-

-

200,000

2,000

28,000

-

128

-
Common
stock returned
pursuant to
agreement

-
-
(500,000)

(5,000)

5,000

-
-
Options
issued at fair
market value

-

-

-
-
422,804

-
-
Net loss for
the year
ended
December 31,
2009

-
-
-
-
-
-
-
-
-
(4,881,878)

Balance,
December 31,
2009

-
\$ -
35,221,650
\$352,217
\$17,463,580
\$ -
\$(15,656,425)

The accompanying notes are an integral part of these consolidated financial statements.

REFLECT SCIENTIFIC, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

For the Years Ended

December 31,

	2009	2008
Net loss		
\$		
	(4,881,878)	
\$		
	(2,164,396)	
Adjustments to reconcile net income to net cash		

provided by
operating activities:

Depreciation

146,157

64,636

Amortization

403,835

383,974

Amortization of
Debenture Discount

584,250

1,272,000

Common stock
issued for
services/interest

153,357

	109,593
Bad Debt	
	30,980
	2,433
Stock based compensation	
	422,804
	29,943
Impairment of long-lived assets	
	708,265
	-
Loss on sale of assets	
	9,797
	-
Penalty for default on debentures	
	690,000

-

Changes in operating
assets and liabilities:

(Increase) / decrease
in accounts receivable

451,963

363,472

(Increase) / decrease
in other receivables

28,583

(301)

(Increase) / decrease
in inventory

173,917

(37,619)

Increase / (decrease)
in income tax
receivable

-
38,000
(Increase) / decrease in prepaid asset
164,868
155,749
(Increase) / decrease in deposits
19,489
-
(Increase) / decrease in cost and estimated earnings in excess of contract billings
649,270
(692,905)
Increase / (decrease) in contract billings in excess of cost and estimated earnings
(164,761)

82,055

Increase / (decrease)
in royalties payable

(51,008)

19,985

Increase / (decrease)
in accounts payable
and accrued
expenses

182,582

87,276

Net Cash from
Operating Activities

(275,130)

(286,105)

CASH FLOWS
FROM INVESTING

ACTIVITIES

Cash paid for fixed
assets

(3,741)

(394,050)

Cash paid for
intangible assets

-

(7,790)

Net Cash from
Investing Activities

(3,741)

(401,840)

CASH FLOWS
FROM FINANCING
ACTIVITIES

Change in long term
line of credit

108

(6,164)

Principle payments on
capital leases

(20,641)

(20,016)

Proceeds from related
party loan

18,000

-

Contributed capital

-

7,000

Net Cash from
Financing Activities

(2,533)

(19,180)

NET INCREASE
(DECREASE) IN
CASH

(281,404)

(707,125)

CASH AT
BEGINNING OF
PERIOD

447,037

1,154,162

CASH AT END OF
PERIOD

\$

165,633

\$

447,037

SUPPLEMENTAL
CASH FLOW
INFORMATION:

Cash Paid For:

Interest

\$
122,390

\$
155,500

Income taxes

\$
800

\$
800

NON-CASH
FINANCING
ACTIVITIES:

Common stock issued
for services

\$
89,250

\$
-

Property exchanged
for relief of liabilities

\$
17,263

-

Stock issued for debt

\$

102,000

-

The accompanying notes are an integral part of these consolidated financial statements.

REFLECT SCIENTIFIC, INC. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

December 31, 2009 and 2008

NOTE 1 -

ORGANIZATION AND DESCRIPTION OF BUSINESS

Cole, Inc. (the Company) was incorporated under the laws of the State of Utah on November 3, 1999. The Company was organized to engage in any lawful activity for which corporations may be organized under the Utah Revised Business Corporation Act. On December 30, 2003 the Company changed its name to Reflect Scientific, Inc.

Reflect Scientific

Reflect Scientific designs, develops and sells scientific equipment for the Life Science and Manufacturing industries. Our business activities include the manufacture and distribution of unique laboratory consumables and disposables such as filtration and purification products, customized sample handling vials, electronic wiring assemblies, high temperature silicone, graphite and vespel/graphite sealing components for use by original equipment manufacturers (OEM) in the chemical analysis industries, primarily in the field of gas/liquid chromatography.

The Company s chemical detector products serve the analytical instrumentation sector of the Life Sciences market. These optically based chemical detection instruments provide a cost-effective, high-performance alternative for original equipment manufacturers (OEM). One major use for these detectors is the analysis of whole blood for metabolic diseases.

Cryometrix

The Company s Cryometrix ultra low temperature freezers are a technological breakthrough that provide energy savings and other critically important benefits to cryo-storage customers in the Life Science related industries. Ultra low temperature freezers are used in multiple industries for the storage of everything from blood to cancer vaccines. These freezers are used by companies and organizations such as the Red Cross, hospitals and biotechnology research facilities. The adaptation of the freezer technology to refrigeration systems used on trailers (reefers) for transporting perishable items opens a significant new market. Trailers can easily be retrofit with the Cryogenix unit, which provides pollutant free and more efficient operations at a cost savings compared to the diesel powered units currently used. The reefer market is a \$1 billion market. The non-polluting Cryogenix unit provides significant benefits over

any other unit currently marketed.

Inspection and Testing Equipment

Image Labs and Miralogix, the companies that manufactured and sold inspection and testing equipment, was divested effective March 2, 2010. See Footnote 18.

NOTE 2 -

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

a. Accounting Method

The Company's financial statements are prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a December 31 year-end.

b. Revenue Recognition

Revenue is only recognized on product sales once the product has been shipped to the customers, persuasive evidence of an agreement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured.

The Company also recognizes revenue on long-term contracts using the percentage-of-completion method. We generally recognize revenue using the percentage-of-completion method for original equipment that requires a minimum of six months to produce. When using the percentage-of-completion method, sales and gross profit are recognized as work is performed based on the relationship between actual costs incurred and total estimated costs at completion. Estimated losses are recognized in full when identified. The asset costs and estimated earnings in excess of contract billings on uncompleted contracts represents revenues recognized in excess of amounts billed. The liability, contract billings in excess of costs and estimated earnings on uncompleted contracts, represents billings in excess of revenues recognized.

c. Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

d. Cash and Cash Equivalents

The company considers all deposit accounts and investment accounts with a maturity of 90 days or less to be cash equivalents.

e. Accounts Receivable

The Company writes off trade receivables when deemed uncollectible. The Company estimates allowance for doubtful accounts based on the aged receivable balances and historical losses. The Company charges off uncollectible accounts when management determines there is no possibility of collecting the related receivable. The Company considers accounts receivable to be past due or delinquent based on contractual terms, which is generally net 30 days.

The Company charged \$30,980 and \$2,433 to bad debt expense for the years ended December 31, 2009 and 2008, respectively. The allowance for doubtful accounts balance at December 31, 2009 and 2008 was \$80,161.

f. Fixed Assets

Fixed assets are stated at cost. Expenditure for minor repairs, maintenance, and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 5 to 7 years, except for computer equipment, which is depreciated over a 3 year life.

g. Inventory

Inventories are stated at the lower of cost or market value based upon the First-In First-Out (FIFO) inventory method. The Company's inventory consists of parts for scientific vial kits, refrigerant gases, components for the imaging and inspection systems which it builds, and other scientific items.

h. Advertising Expense

The Company follows the policy of charging the costs of advertising to expense as incurred. The Company recognized \$5,377 and \$62,330 of advertising expense during the years ended December 31, 2009, and 2008, respectively.

i. Newly Issued Accounting Pronouncements

On July 2009, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (the Codification) officially became the single source of authoritative nongovernmental U.S. Generally Accepted Accounting Principles (GAAP), superseding existing FASB, American Institute of Certified Public Accountants, Emerging Issues Task Force, and related accounting literature. Going forward, only one level of authoritative GAAP will exist. All other accounting literature will be considered non-authoritative. The Codification reorganizes the thousands of GAAP pronouncements into roughly 90 accounting topics and displays them using a consistent structure. Also included in the Codification is relevant SEC guidance organized using the same topical structure in separate sections within the Codification. The Codification was effective for interim and annual reports ending after September 15, 2009. The Company adopted the Codification during the fourth quarter of fiscal 2009. The impact on its financial statements is limited to disclosures. All references to authoritative accounting literature will now be referenced in accordance with the Codification.

ASC Topic 855 (Formerly SFAS 165) In May 2009, the FASB issued ASC Topic 855, Subsequent Events. ASC Topic 855 establishes standards of accounting for the disclosure of events that occur after the balance sheet date but before financial statements are issued. Financial statements are considered available to be issued when they are complete in a form and format that complies with GAAP and all approvals necessary for issuance have been obtained. An entity is to apply the requirements to interim or annual financial periods ending after June 15, 2009. The Company adopted the provisions of ASC Topic 855 for the quarter ended September 30,, 2009.

ASC Topic 860 (Formerly SFAS 166) In June 2009, the FASB issued ASC Topic 860, Accounting for Transfers of Financial Assets an amendment of FASB Statement No. 140. ASC Topic 860 requires entities to provide more information about sales of securitized financial assets and similar transactions, particularly if the seller retains some risk to the assets. The statement eliminates the concept of a qualifying special-purpose entity, changes the requirements for the de-recognition of financial assets, and calls upon sellers of the assets to make additional disclosures about them. ASC Topic 860 is effective for transactions occurring on or after November 15, 2009. The Company does not expect the adoption of ASC Topic 860 will have a material impact on its financial statements.

ASC Topic 810 (Formerly SFAS 167) In June 2009, the FASB issued ASC Topic 810, Amendments to FASB Interpretation No. 46(R). ASC Topic 810 amends Interpretation No. 46(R) to require enhanced disclosures that will provide users of financial statements with more transparent information about an enterprise s involvement in a variable interest entity. ASC Topic 810 is effective for an entity s first fiscal period that begins after November 15, 2009. The Company does not expect the adoption of ASC Topic 810 will have a material impact on its financial statements.

ASC Topic 105 (Formerly SFAS 168) In June 2009, the FASB issued ASC Topic 105, The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles a replacement of FASB Statement No. 162. ASC Topic 105 establishes a new hierarchy of GAAP sources for non-governmental entities under the FASB Accounting Standards Codification and will supersede all accounting standards in U.S. GAAP, aside from those issued by the Securities Exchange Commission. ASC Topic 105 is effective for financial statements issued for interim and annual periods ending after September 15, 2009. The Company does not expect the adoption of ASC Topic 105 will have a material impact on its financial statements.

In October 2009, the FASB issued ASU No. 200-13, Revenue Recognition Multiple Deliverable Revenue Arrangements (ASU 2009-13). ASU 2009-13 updates the existing multiple-element revenue arrangements guidance

currently included in FASB ASC 605-25. The revised guidance provides for two significant changes to the existing multiple-element revenue arrangements guidance. The first change relates to the determination of when the individual deliverables included in a multiple-element arrangement may be treated as separate units of accounting. This change will result in the requirement to separate more deliverables within an arrangement, ultimately leading to less revenue deferral. The second change modifies the manner in which the transaction consideration is allocated across the separately identified deliverables. Together,

these changes will result in earlier recognition of revenue and related costs for multiple-element arrangements than under previous guidance. This guidance expands the disclosures required for multiple-element revenue arrangements. Effective for interim and annual reporting periods beginning after December 15, 2009. The Company is currently evaluating the potential impact, if any, of this guidance on its financial statements.

The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its consolidated results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its current or future earnings or operations.

j. Basic Earnings per Share

The computation of earnings per share of common stock is based on the weighted average number of shares outstanding during the period of the consolidated financial statements as follows:

	For the Years Ended
	December 31,
	2009
	2008
Net loss (numerator)	
\$	(4,881,878)
\$	(2,164,296)

Shares
(denominator)

34,981,966

34,359,453

Net loss per
share amount

\$

(0.14)

\$

(0.06)

As of December 31, 2009 the Company had 14,395,215 shares of outstanding common stock equivalents, but due to the net loss, they were not included in the calculation of the net loss per common share as their inclusion would be anti-dilutive.

k. Shipping and Handling Fees and Costs

The Company records all shipping and handling cost in cost of goods sold.

l. Income Taxes

Deferred taxes are provided on an asset and liability approach whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

The Company's policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the years ended December 31, 2009 and 2008, it did not recognize any interest or penalties in its Statement of Operations, nor did it have any interest or penalties accrued in its Balance Sheet at December 31, 2009 and 2008 relating to unrecognized benefits.

m. Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries, which include Cryometrix (previously Cryomastor), All Temp Engineering and Image Labs International. All subsidiaries are wholly owned. All material intercompany accounts and transactions are eliminated in consolidation.

n. Research and development expense

The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board's Accounting Standard Codification Topic 730 "Research and Development". Under ASC730, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company had \$307,433 and \$297,402 in research and product development for the years ended December 31, 2009 and 2008, respectively.

o. Stock Based Compensation

The Company applies the provisions of FASB ASC Topic 718 "Stock Based Compensation" which requires companies to measure all employee stock-based compensation awards using a fair value method and record such expense in their financial statements.

p. Intangible Assets

Intangible assets include trademarks, trade secrets, patents, customer lists and goodwill acquired through acquisition of subsidiaries. The patents have been registered with the United States Patent and Trademarks Office. The costs of obtaining patents are capitalized as incurred. Intangibles, except for goodwill, are amortized over their estimated useful lives.

q. Impairment

The Company reviews long-lived assets, at least annually, to determine if impairment has occurred and whether the economic benefit of the asset (fair value for assets to be used and fair value less disposal cost of assets to be disposed) is expected to be less than the carrying value. Triggering events, which signal further analysis, consist of a significant decrease in the asset's market value, a substantial change in the use of an asset, a significant physical change in the asset, a significant change in the legal or business climate that could affect the asset, an accumulation of costs significantly in excess of the amount originally expected to acquire or construct the asset, or a history of losses that imply continued losses associated with assets used to generate revenue. The impairment analysis conducted subsequent to year-end recognized that certain long-lived assets were impaired due to changed business conditions and a change in business direction. As a result of that analysis, an impairment charge of \$708,265 and \$0 was recorded at December 31, 2009 and 2008 respectively.

NOTE 3 GOING CONCERN

The Company is currently in default on the issued and outstanding debentures. While the Company is working diligently to secure funding to enable it to retire the debenture obligations, there can be no assurance that such funding will be available. The Company has also accumulated significant operating losses. These factors raise substantial doubt about the Company's ability to continue as a going concern.

Management has taken a number of actions to reduce expenses including reductions in personnel, consolidation of facilities, and the downsizing of the unprofitable service and maintenance operations conducted by All Temp Engineering. Management has reached settlement agreements on the majority of the debentures that are in default, which settlement is contingent upon their ability to pay \$400,000 in cash, with the remaining balance being converted into shares of the Company's restricted common stock. Management is seeking additional funding through the capital markets to facilitate this settlement, as well as to provide operating capital for its operations. Management has also made the decision to discontinue certain operations (See Footnote 18 - Subsequent Events). The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

NOTE 4 -

FIXED ASSETS

Fixed assets and related depreciation for the period are as follows:

December 31,
2009

December 31,
2008

Machinery and
equipment

\$
510,945

\$
508,324

Furniture and
fixtures

33,506

71,042

Computer and
o f f i c e
equipment

67,234

72,623

Vehicles

3,300

33,625

Leasehold
improvements

29,279

31,719

Accumulated
depreciation

(224,442)

(128,035)

Total Fixed
Assets

\$

419,822

\$

589,298

Depreciation expense for the years ended December 31, 2009, and 2008, was \$146,157 and \$64,636, respectively.

NOTE 5 -

INVENTORIES

Inventory consisted of the following at December 31, 2009 and 2008:

December
31,

2009

December
31,

2008

Work in
Process

\$

164,122

\$

63,215

Finished
goods

427,550

702,374

Total
Inventory

\$

591,672

\$

765,589

NOTE 6-

COMMITMENTS AND CONTINGENCIES

Operating Lease Obligations

The Company leases its office and warehouse space under non-cancelable lease agreements accounted for as operating leases. The Company also leases several automobiles under similar non-cancelable lease agreements, which are also accounted for as operating leases.

Orem, Utah This facility is a manufacturing and office facility with 6,000 square feet of space. We lease this facility at \$3,800 per month, with the lease term expiring on November 30, 2014.

Bozeman, Montana This facility is a manufacturing and office facility with 9,140 square feet of space. We lease this facility at \$9,801 per month, with the lease term expiring on May 31, 2011. Subsequent to year end the lease was assumed by the purchasing entity (See Note 18).

Minimum rental payments under the non-cancelable operating leases are as follows:

Years
ending

December
31,

Amount

2010

\$

174,312

2011

124,244

2012

52,528

2013

54,366

2014

51,430

\$

456,880

Rent expense was \$304,758 and \$277,463 for the years ended December 31, 2009, and 2008, respectively.

Automobile lease expense was \$10,264 and \$11,097 for the years ended December 31, 2009, and 2008, respectively.

NOTE 7-

CAPITAL LEASES

During the year ended 2006, the Company entered into two capital lease arrangements for the purchase of equipment. Payments are due in 60 and 36 monthly installments of \$920 and \$1,101. The leases have a stated interest rate of 8.3%

Aggregate maturities on the capital leases as of December 31, 2009, are due in future years as follows:

2010

\$

9,791

2011

9,715

Total

19,506

Depreciation expense on equipment under capital leases was \$12,655 and \$12,655 for the years ended December 31, 2009 and 2008, respectively. The capital leases are collateralized by a leak test system which has a current net book value of \$27,471.

NOTE 8 -

PREFERRED STOCK

In November 2004 the Company amended its Articles of Incorporation so as to authorize 5,000,000 shares of preferred stock. 750,000 of these shares have been designated as Series A Convertible Preferred Stock . As of December 31, 2009 no shares of the preferred stock are issued and outstanding.

Dividends

The holders of the Series A Preferred Stock are entitled to dividends at the rate of 8 percent per year of the liquidation preference of \$1.00 per share, payable annually, if and when declared by the board of directors. Dividends are not cumulative and the board of directors is under no obligation to declare dividends.

Convertibility

Upon the approval of the Board of Directors, Series A Preferred Stock may be convertible into the Company's common stock by dividing \$1.00 plus any unpaid dividends by 50% of the five day average closing bid price of the common shares.

NOTE 9 -

COMMON STOCK TRANSACTIONS

During the year ended December 31, 2009, the Company issued 320,450 shares of common stock for interest payments, 273,590 shares of common stock for the conversion of debt, and 600,000 shares of common stock for consulting services. and 25,000 shares were issued to a former employee. An original shareholder of All Temp Engineering returned 500,000 shares of stock issued to him in the All Temp acquisition transaction, which shares were cancelled. During the year ended December 31, 2008, the Company issued 189,765 shares of common stock for interest payments and 212,307 shares were issued for the conversion of debt.

NOTE 10 -

CONCENTRATIONS OF RISK

Cash in Excess of Federally Insured Amount

The Company does not currently maintain a cash balance at a single financial institution in excess of the federally insured maximum of \$250,000. The excess as of December 31, 2009 and 2008 was \$0 was \$160,298, respectively.

NOTE 11 -

LINE OF CREDIT

The Company has a credit line with a commercial bank of \$100,000 secured by its inventory and accounts receivable bearing a variable interest rate, which was 5.50% as of the balance sheet date, and has no stated maturity date. As of December 31, 2009, there was a balance due on the line in the amount of \$93,012.

The Company has an additional credit line with a different commercial bank of \$50,000 secured by its inventory and accounts receivable bearing a fixed interest rate, which was 7.75% as of the balance sheet date, and has no stated maturity date. As of December 31, 2009, there was a balance due on the line in the amount of \$48,464.

NOTE 12 CONVERTIBLE DEBENTURES AND WARRANTS

On June 29, 2007, the Company entered into an agreement to sell \$2,500,000 in 12% senior convertible debentures with a maturity date of June 29, 2009, with interest due quarterly. At the closing, the Company prepaid the first quarterly interest payment and reserved the second quarterly interest payment of \$150,000. The agreement allows for the Company to pay the interest in cash or in duly authorized, validly issued, fully paid, and non-assessable shares of common stock at the interest conversion rate, or a combination thereof. The conversion is based on 85% of the volume weighted average stock price for the preceding 10 days.

The debentures have a conversion price of \$0.65. If the Company, at any time while the debenture is outstanding, pays stock dividends, subdivides outstanding shares, sells or grants any option to purchase or dispose of common stock at an effective price lower than the conversion price, issue rights, options or warrants at a price lower than the conversion price, etc., the Company shall promptly deliver to each Holder a notice setting forth the conversion price after such adjustment and provide a brief statement of facts requiring such adjustment. In addition, if the volume weighted average price for each of any 20 consecutive trading days exceeds 250% of the conversion price, the Company may, within one trading day deliver a written notice to the holder and force the holder to convert a principal amount of the debenture equal to all or part of the holder's portion of the forced conversion amount.

The agreement also provides for the issuance of 1,923,077 A warrants and 1,923,077 B warrants. The warrants are exercisable at a price of \$0.80 per share for the A warrant and \$1.00 per share for the B warrant and expire June 29, 2012. The Company valued the warrants using the Black-Scholes option pricing model. For the purpose of the valuation of the warrants, the Company calculated a volatility of 66.48% on its common stock and used the U. S. Treasury bill rate of 4.94% for its risk free rate. Then the Company allocated a portion of the proceeds to the

warrants, based on the relative fair value basis, in the amount of \$1,639,029 which was recognized as a contra liability account and was amortized as interest expense over the 2 year term of the agreement. The intrinsic value of beneficial conversion of the debentures was valued at \$5,677,491, which exceeds the effective value of the debentures by \$860,971. Therefore, the discount assigned to the beneficial conversion feature is limited to \$860,971 and was recognized as a contra liability account and was amortized as interest expense over the 2 year term of the agreement.

As payment for services provided, the Company also issued 192,308 Series A warrants and 192,308 Series B warrants which were valued at \$475,925 using the Black-Scholes option pricing model and expensed in 2007.

The debentures and warrants have anti-dilution protections, and the Company agreed to certain registration rights for the resale of the shares of common stock underlying the debentures and warrants.

A summary of the status of the Company's outstanding stock warrants as of December 31, 2009 and changes during the period then ended is presented below:

Shares
Weighted Average Exercise Price
Outstanding, January 1, 2008
-
\$
-
Granted
4,151,895

.90

Expired/Cancelled

-

-

Exercised

-

-

Outstanding,
December 31,
2008

4,151,895

.90

Expired/Cancelled

-

-

Exercised

-

-

Outstanding,
December 31,
2009

4,151,895

\$

.90

Exercisable

4,151,895

\$

.90

Outstanding

Exercisable

Range of
Exercise
Prices

Number
outstanding at
December 31,
2009

Weighted
Average
Remaining
Contractual
Life

Number
Exercisable at
December
31,2009

\$

0.80

2,036,510

2.50

2,036,510

1.00

2,115,385

2.50

2,115,385

4,151,895

4,151,895

At December 31, 2009, the outstanding indebtedness for the debentures and penalty resulting from forfeiture was \$2,925,000. Assuming all debentures were converted, 4,500,000 shares of restricted common stock would be issued.

Additionally, assuming all outstanding warrants were exercised, the total shares issued from conversion and exercise would total 8,651,895 shares.

NOTE 13 COMMON STOCK OPTIONS

On December 31, 2007, the Company's board of directors approved an equity plan. The equity plan known as the 2007 Equity Incentive Plan (the Plan) reserves up to 6,000,000 shares of the Company's authorized common stock for issuance to officers, directors, employees and consultants under the terms of the Plan. On December 31, 2009, the Company's board of directors amended the Plan to authorize 12,000,000 shares. The Plan permits the board of directors to issue stock options and restricted stock.

Edgar Filing: REFLECT SCIENTIFIC INC - Form 10-K

The fair value of each option granted under the Plan is estimated on the date of grant, using the Black-Scholes option pricing model, based on the following weighted average assumptions:

**Options
granted
December
31, 2007:**

Expected
life (years)

5.0

Expected
stock price
volatility

66.27

%

Expected
dividend
yield

0.0

%

Risk-free
interest
rate

3.38

%

**Options
granted
December
31, 2008:**

Expected
life (years)

5.0

Expected
stock price
volatility

65.79

%

Expected
dividend
yield

0.0

%

Risk-free
interest
rate

3.41

%

**Options
granted
December
31, 2009:**

Expected
life (years)

5.0

Expected
stock price
volatility

88.22

%

Expected
dividend
yield

0.0

%

Risk-free
interest
rate

2.34

%

The risk-free interest rate is based upon the U.S. Treasury yield curve at the time of grant for the respective expected life of the option. The expected life (estimated period of time outstanding) of options was estimated. The expected volatility of the Company's options was calculated using historical data. Expected dividend yield was not considered in the option pricing formula since the Company does not pay dividends and has no current plans to do so in the future. If actual periods of time outstanding and rate of forfeitures differs from the expected rates, the Company may be required to make additional adjustments to compensation expense in future periods.

The Company granted options to purchase 5,000,000 shares of common stock to key directors on December 31, 2007. On June 13, 2008, the Company granted options to purchase 66,660 shares of common stock to employees. On December 31, 2009, the Company granted options to purchase 5,176,660 shares of common stock to certain officers, directors and employees. A summary of the status of the Company's outstanding stock options as of December 31, 2009 and changes during the period then ended is presented below:

Shares

Weighted Average
Exercise PriceOutstanding,
January 1, 2008

5,000,000

\$
1.32

Granted
66,660

0.94

Expired/Cancelled
-

-

Exercised
-

-

Outstanding,
December 31,
2008

5,066,660

1.31

Granted

5,176,660

0.13

Expired/Cancelled

-

-

Exercised

-

-

Outstanding,
December 31,
2008

10,243,320

\$

0.71

Exercisable

10,243,320

\$

0.71

42

Outstanding

Exercisable

Range of
Exercise
Prices

Number
outstanding at
December 31,
2008

Weighted
Average
Remaining
Contractual
Life

Number
Exercisable at
December
31,2008

\$

1.32

4,800,000

4.00

4,800,000

1.30

14,000

4.45

14,000

1.20

200,000

4.00

200,000

0.85

52,660

4.45

52,660

0.13

4,800,000

10.00

4,800,000

0.12

376,660

10.00

376,660

10,243,320

10,243,320

The total fair value of options vested was \$422,804 and \$29,943 for the years ended December 31, 2009 and 2008, respectively. As of December 31, 2009, there was no unrecognized compensation cost related to non-vested stock options granted under the Plan. The 5,176,660 options granted in 2009 fully vested during the year and have been expensed.

NOTE 14 INTANGIBLE ASSETS

Intangible assets are stated at cost. Amortization computed using the straight-line method. The lives over which the intangible assets are amortized range from 10 to 20 years. Intangible assets and related amortization for the period are as follows:

2008

Accumulated

Cost

Amortization

Net Book Value

Trademarks

\$ 135,719

\$ 25,529

\$ 123,861

Trade Secrets

437,875

82,468

355,407

Patents

3,523,967

536,054

2,987,913

Customer lists

1,326,977

278,284

1,048,693

Goodwill

970,648

-

970,648

Totals

\$ 6,395,186

\$ 922,335

\$ 5,472,851

2009

Accumulated

Cost

Amortization

Net Book Value

Trademarks

\$ 87,525

\$ 37,358

\$ 50,167

Trade Secrets

375,807

126,255

249,552

Patents

3,523,967

751,283

2,772,684

Customer lists

1,047,222

411,022

636,200

Goodwill

652,149

-

652,149

Totals

\$ 5,686,670

\$ 1,308,393

\$ 4,360,722

Amortization expense for the years ended December 31, 2009, and 2008, was \$396,030 and \$406,400, respectively.

NOTE 15 ROYALTIES

Royalty agreements were executed with JMST, Cryometrix, All Temp and Image Labs as a condition of the companies acquisitions. Terms of the royalty agreements are as follows:

JMST David Carver will receive a royalty payment on gross revenues related to revenues derived from the Carver Patents or Carver Technology. Such payments are due on revenue in excess of \$500,000 derived from products under the Carver Patents or Carver Technology. The royalty payment is 2.5% on the revenue in excess of \$500,000 and is payable quarterly. Payments are to be made in Reflect Scientific's common stock not to exceed 500,000 shares in total. New products developed from the Carver Technology are subject to a royalty of 3% of gross revenues in excess of \$100,000, with an additional 2% if gross revenues exceed \$600,000. Royalties will also be paid in our common stock annually. Common stock will be valued at \$3.00 per share for these purposes. Royalty payments are only due for years where there are valid Carver Patents. At December 31, 2009, there were no royalties due.

Cryometrix The prior shareholders of Cryometrix receive a 2.5% royalty on all sales, licensing or other distributions on revenue derived from products and technology received from Cryometrix. The royalty payment is not due or payable unless and until the revenue derived from such products and technology exceeds \$3,000,000. The payment is payable in shares of Reflect Scientific's common stock not to exceed 2,000,000 shares in aggregate. Common stock will be valued at \$1.80 or market value at time of accrual which ever is greater, for these purposes. Payments are due quarterly. At December 31, 2009, there were no royalties due.

All Temp The shareholders of All Temp will receive a pro-rata running royalty totaling 5% of the gross annual revenues earned from the All Temp's business unit. This revenue covers all revenues received by the All Temp subsidiary or any other business unit of Reflect Scientific which revenue is derived from products or services derived from All Temp as part of its acquisition. The royalty is payable as long as Reflect Scientific owns and operates the All Temp business provided that the royalty is not payable if the All Temp business does not have earnings of at least 10% measured by earnings before interest and taxes. The royalty is payable quarterly within 45 days following the close of each quarter. If within three years of the closing of the acquisition of All Temp, Reflect Scientific sells or transfers All Temp, its products or services, All Temp shareholders shall receive a cash payment of six hundred thousand dollars less any accumulated royalties payable. At December 31, 2009, there were no royalties due.

Image Labs The shareholders of Image Labs will receive a running earnout on the gross revenues derived from products associated with Image Labs including value added re-sales and custom engineering business segments. The earnout is established as 1.25% of all gross revenues and an additional 1.25% of all revenues if the company achieves EBIT of 10%. This segment specifically excludes anything received from our Catpro product lines. The royalty is

payable quarterly so long as Reflect Scientific owns the Image Labs product line and services and as long as the business segment achieves an earnings before interest and taxes of 10% in the quarter the royalty payments are due. At December 31, 2009, there were \$22,542 royalties due.

NOTE 16 INCOME TAXES

The provision (benefit) for income taxes for the year ended December 31, 2009 and 2008 consist of the following:

2009

2008

Federal:

Current

\$

-

\$

-

Deferred

-

38,000

State:

Current

3,116

900

Deferred

-

-

\$

3,116

\$

38,900

Net deferred tax assets consist of the following components as of December 31, 2009 and 2008:

2009

2008

Deferred tax assets:

NOL Carryover

\$

2,730,600

\$

1,302,363

Stock Based
Compensation

1,397,938

1,140,209

Depreciation and
Amortization

102,052

-

R&D Tax Credits

51,627

-

Other Reserves

38,642

-

V a l u a t i o n
A l l o w a n c e

(4,320,860)

(2,442,572)

T o t a l

-

-

D e f e r r e d t a x
l i a b i l i t i e s :

-

	-
Net deferred tax asset (liability)	
\$	-
\$	-
	-

The income tax provision differs from the amount of income tax determined by applying the U.S. federal and state income tax rates of 34% to pretax income from continuing operations for the year ended December 31, 2009 and 2008 due to the following.

2009

2008

Expected Tax Expense

\$

(1,658,779)

\$

(722,660)

Non deductible
Expenses

1,900

9,268

R&D Tax Credit

(51,627)

-

Stock for Services

43,523

37,947

Warrant Amortization

198,645

432,480

State Tax Effect

(163,620)

-

Other, net

(245,214)

65,924

Change in Valuation
Allowance

1,878,288

215,950

\$

3,116

\$

38,900

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryforwards for Federal income tax reporting purposes are subject to annual limitations. If a change in ownership occurs, then net operating loss carryforwards may be limited as to use in future years. At December 31, 2009, the Company had net operating loss carryforwards of approximately \$7,185,866 that may be offset against future taxable income from the year 2009 through 2029. In addition the Company had research and development tax credit carryforwards of \$51,627. During 2009 the company reevaluated its deferred tax assets and concluded that none of the asset would be realizable and that a full valuation allowance should be recorded. The valuation allowance was increased by \$1,878,288 and leaves the company with a net deferred tax asset of \$0 as of December 31, 2009.

Included in the balance at December 31, 2009, are no tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. Because of the impact of deferred tax accounting, other than interest and penalties, the disallowance of the shorter deductibility period would not affect the annual effective tax rate but would accelerate the payment of cash to the taxing authority to an earlier period.

The tax years 2008 and 2007 remain open to examination for federal income tax purposes and by the other major taxing jurisdictions to which we are subject.

Loan from Shareholder

At December 31, 2009, a shareholder of the Company had advanced \$18,000 in funding in the form of a non-interest bearing loan to the Company. It is the intent of the Company to repay this loan upon the closing of a major capital raise.

NOTE 18 SUBSEQUENT EVENTS.

The Company has evaluated subsequent events through March 31, 2010, the date the financial statements were issued, and has concluded that no recognized subsequent events have occurred since the year ended December 31, 2009. The Company does note the following non-recognized transactions occurred subsequent to the year end:

Debenture Settlement Agreement

In February 2010, management reached agreement with Enable on a plan to settle the debentures held by Enable that are in default. The settlement agreement is contingent upon the Company making a cash payment to Enable in the amount of \$400,000, which amount will be used to reduce the outstanding principle and penalty currently in default. Upon receipt of the \$400,000 payment, the balance of the principle and penalty will be converted into shares of the Company's common stock at the rate of \$0.40 per share. The Company is currently working on raising the funding to enable it to fulfill the payment obligation under this agreement. Should the Company successfully raise the necessary funding and make the \$400,000 payment specified under the settlement agreement, the conversion of the remaining debenture and penalty balance of \$1,875,000 would result in the issuance of 4,687,500 shares of restricted common stock.

Divestiture of Image Labs and Miralogix

On March 2, 2010, Image Labs and Miralogix were sold to an employee. Under the terms of the agreement all assets were transferred and all liabilities, except those employee related liabilities, such as salary, payroll taxes, and IRA contributions, were assumed by the new owner. The sale of these entities, which manufacture and sell imaging and inspection devices and systems, will enable the Company to focus on its core green technology businesses. While the Company received no cash from the transaction, the acquirer assumed all of the Company's liabilities, except those related to accrued payroll, as well as taking possession of the assets.

